Targeting Lipids to Improve Outcomes in Your Cath Patients

Overview

This activity is designed to provide Interventional Cardiologists with the knowledge and tools necessary to improve lipid management in cath patients. By focusing on the genetic basis of lipid disorders, addressing undertreatment, optimizing the use of lipid-lowering therapies, and implementing effective secondary prevention strategies, ICs are poised to enhance patient outcomes.

Faculty and Program

	David Zidar, MD, PhD, FSCAI Genetic Basis of Lipoprotein (a), ApoB, and Lipid Analysis in Contemporary Practice		Subhash Banerjee, MD, FSCAI Undertreatment and Opportunity in Lipid Lowering Therapy for Patients with Coronary and Peripheral Artery Disease
	Peter Monteleone, MD, FSCAI Statins and Non-statin Therapy: For Whom and When		Suzanne J. Baron, MD, FSCAI Championing Strategies for Secondary Prevention in Your Cath Patients

Learning Objectives

Upon completion of this activity, participants will be able to:

Discuss testing strategies for lipoprotein (a), apoB, and lipid analysis in contemporary practice.
Recognize system-level gaps and explore system-based strategies to provide optimal guideline directed lipid-lowering therapy for secondary prevention.
Clarify when to use statins and non-statin therapies to achieve lipid targets.
Empower patients with knowledge necessary to make decisions about setting and achieving their target lipid levels.

Accredited Continuing Education Information

This activity is not certified for CME.

Record Date: 12-14-24
Publication Date: 1-9-25
Retire Date: 1-8-28

Summary


Availability:	On-Demand
	Access expires on 01/08/2028


Cost:	Member: $0.00 Non-Member: $19.00 Fellow-In-Training: $0.00 Cardio Team Member: $0.00


Credit Offered:	0.75 Participation Credit